Objectives

Burden of Disease
 Disability Adjusted Life-Years (DALY) is the unit measure of disease burden. This indicator combines the years of potential life lost due to premature mortality (YLL) and the years of healthy life lost due to disability (YLD). 4

The YLL correspond to the number of deaths multiplied by the socially weighted and discounted life expectancy at the age at which death occurs using a standardized life 
Burden of Disease
Years of Life Lost (YLL)
 A total of 3,180 deaths in Portugal in 2012 were caused by NSCLC. Male deaths account for 78% of all NSCLC deaths. In 2012 NSCLC mortality accounted for 3.0% of total mortality in Portugal.

The estimated YLL added up to 25,071, representing 4.5% of the total years of life lost for all deaths in the country.
Years Lost due to Disability (YLD)

In 2012 an incidence of 3,613 new cases was estimated for NSCLC in Portugal.
The estimated mean duration of the disease for patients diagnosed in a locoregional stage (I to IIIA) was 2.8 years, while it was 1.2 years for patients diagnosed in an advanced stage (IIIB to IV).
The mean disability weight for the locoregional stages was 0.499 and for the advanced stages was 0.869.
The total estimate of YLD attributed to NSCLC in Portugal was 3,236.
Overall disease burden

The global burden of NSCLC was estimated to be 28.307 DALY (Table 1) .
 YLL represented 89% of the total DALY, underlining the impact of this disease in terms of mortality.
Cost of illness

The estimated direct cost attributable to NSCLC in 2014 prices is € 89 million which can be broken down into € 32 million for inpatient care and € 57 million for outpatient care.
The indirect costs due to disability add up to € 54 million: € 4 million from the locoregional stages and € 50 million from advanced stages. These estimates include both long run effects such as premature retirement and short run effects such as absenteeism.  NSCLC is an important cause of disease burden, accountable for 28,307 DALY.
YLL YLD DALY

The majority of NSCLC burden is due to mortality.
The disease burden falls mostly on male patients.
The overall costs of disease are estimated at € 143 million, about 0.1% of Portuguese GDP and 0.9% of the overall Portuguese 2012 health expenditure.
The costs and burden of disease suggest that NSCLC has a sizeable impact on Portuguese health costs and society ´s welfare. Consequently NSCLC should receive appropriate attention from policy makers.
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